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Abstract
Background: Thoracic aortic aneurysms and dissections (TAAD) is a critical condition that often goes undiagnosed
with fatal consequences. While majority of the cases are sporadic, more than 20% are inherited as a single gene
disorder. The most common familial TAA is Marfan syndrome (MFS), which is primarily caused by mutations in
fibrillin-1 (FBN1) gene. Patients with FBN1 mutations are at higher risk for dissection compared to other patients
with similar size aneurysms.
Methods: Fifteen family members were genotyped using Affymetrix-10K genechips. A genome-wide association
study was carried out using an autosomal dominant model of inheritance with incomplete penetrance. Mutation
screening of all exons and exon-intron boundaries of FBN1 gene which reside near the peak Lod score was carried
out by direct sequencing.
Results: The index case presented with agonizing substernal pain and was found to have TAAD by transthoracic
echocardiogram. The family history was significant for 3 first degree relatives with TAA. Nine additional family
members were diagnosed with TAA by echocardiography examinations. The affected individuals had no syndromic
features. A genome-wide analysis of linkage mapped the disease gene to a single locus on chromosome 15q21
with a peak Lod score of 3.6 at fibrillin-1 (FBN1) gene locus (odds ratio > 4000:1 in favour of linkage), strongly
suggesting that FBN1 is the causative gene. No mutation was identified within the exons and exon-intron
boundaries of FBN1 gene that segregated with the disease. Haplotype analysis identified additional mutation
carriers who had previously unknown status due to borderline dilation of the ascending aorta.
Conclusions: A familial non-syndromic TAAD is strongly associated with the FBN1 gene locus and has a malignant
disease course often seen in MFS patients. This finding indicates the importance of obtaining detailed family
history and echocardiographic screening of extended relatives of patients with non-syndromic TAAD to improve
the outcome. In addition, association of non-syndromic TAAD with the Marfan disease gene locus poses the
question whether secondary prevention strategies employed for Marfan syndrome patients should be applied to all
patients with familial TAAD.
Background
Thoracic aortic aneurysms and dissections (TAAD) is a
lethal condition with a rising incidence [1,2]. Although
this condition often occurs sporadically, about one out of
every 5 cases is familial. This includes syndromic forms
of the disease, including Marfan syndrome (MFS) and
the less commonly seen Loeys-Dietz syndrome as well as
the non-syndromic thoracic aortic aneurysm. The mode
of inheritance in most cases is consistent with autosomal
dominant with incomplete penetrance[3]. It is a hetero-
geneous disorder for which more than 4 loci have been
mapped [4-7].
Marfan syndrome is a connective tissue disorder that
affects multiple organs including cardiovascular and
skeletal systems [7]. It is often inherited as an autosomal
dominant disorder caused by FBN1 gene mutation
[8-12]. Its most lethal complication is aortic aneurysm, a
malignant disorder which results in early onset dissection
and death [13]. Whether FBN1 mutation can cause non-
syndromic familial aneurysm and more importantly if the
disease course is equally malignant is not known.
Absence of syndromic features in FBN1 mutation carriers
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may not have implications for disease screening. This
screening may include obtaining detailed family and an
echocardiographic examination. In addition, the family
history and the disease course in the family members
with advanced disease and complications may impact the
future planning for at risk family members. With the
advent of cost effective high throughput sequencing tech-
niques, mutation screening of patients with thoracic aor-
tic aneurysms for known genes such as FBN1 may
become part of the routine clinical workup.
In the current study, we identified a large three-
generation family with multiple members affected by
early onset TAAD in absence of syndromic features. A




The research protocol was approved by the institutional
review boards of all participating institutions. All study par-
ticipants provided written informed consent for clinical
and genetic studies. Detailed family history was obtained
and extensive physical examination by a clinical geneticist
was carried out. Family members were examined for
musculoskeletal, pulmonary, and dermatological features of
MFS based on Ghent nosology. Ophthalmologic and echo-
cardiographic examinations were carried out by an
ophthalmologist and a cardiologist, respectively. For echo-
cardiographic evaluation of the aneurysms, diameters of
the aorta at the sinus of valsalva, the supra-aortic ridge,
and the aortic root were measured from cross-sectional
echocardiography images in the parasternal long-axis. Indi-
viduals were identified as affected if they had an aneurysm
(diameter ≥3.6 cm at the aortic root or supra-aortic ridge
level) or dissection of the ascending thoracic aorta. MRI
examinations of the lumbosacral region were carried out
on limited number of patients with thoracic aneurysms.
Blood samples were collected from family members. Geno-
mic DNA was isolated from 15 family members.
Genotyping and Analysis of Linkage
Thirteen family members were called as affected (2 were
deceased), 2 as unaffected and 2 as unknown. Affymetrix
10K DNA genechip arrays were used to genotype > 10,000
SNPs across the genome in all 15 living family members.
Allele frequencies for each SNP were mean allele fre-
quencies of 20 unrelated unaffected Iranian (ethnically
matched) and penetrance was set at 90%. Multipoint
analysis of linkage with Genehunter was used for the
genome scan analysis.
Sequence variation detection and functional analysis
All 66 exons and exon-intron boundaries of FBN1 were
amplified by PCR and were evaluated using direct
dye-termination sequencing. Sequences were evaluated
using the sequencer software and were interpreted inde-
pendently by two lab members. Complementary strands
were sequenced to confirm potential substitutions. Skin
biopsies were obtained as part of the clinical workup by
the local dermatologists and were evaluated by the local
diagnostic laboratory using immunocytochemistry.
Results
Clinical Evaluations
We studied a 3-generation Iranian family. The Index
case (individual 6) was a 55 years old woman who pre-
sented with acute substernal chest pain. The echocardio-
graphic examination revealed normal left ventricular
wall motion but dilated aorta with a proximal ascending
aorta diameter of 5.5 cm with evidence for dissection
(Figure 1). Patient was only 170 cm tall, and did not
exhibit disproportionately long extremities compared
with the trunk (dolichostenomelia); no evidence for ara-
chnodactyly was noted. Wrist (Walker) and thumb
(Steinberg) signs were absent and no other musculoske-
letal, pulmonary, ophthalmological or dermatological
abnormalities of the Ghent nosology were identified.
Immediate surgical repair was planned, but the patient
deceased on the way to the operating room. Her older
sister had presented at the age of 51 years with dissec-
tion of a 5 cm ascending aortic aneurysm and the
younger sister had been diagnosed with proximal
ascending aortic dilation involving the aortic root with
moderate aortic regurgitation and both had undergone
Bentall procedures. Interestingly, the son of the index
case presented later with TAAD and had to undergo
Bentall procedure. Ten additional immediate family
members were classified as affected and 2 as unaffected
by echocardiographic examinations (aortic root or
ascending aortic diameter ≥ 3.6 cm, Figure 2). Two
other individuals (14 and 17) had aortic diameters
Figure 1 Ascending aortic dissection. Transthoracic echocardiogram
in index case depicting dissection in proximal ascending aorta.
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(3.2 and 3.1 cm) that were considered relatively large for
their age but did not exceed the cut off for diagnosis
and were assigned the unknown status. No syndromic
feature suggestive of MFS was detected in any of the
family members (Additional File 1).
Mapping of the Locus
A genome-wide analysis of linkage in 15 family members
(11 affecteds, 2 unaffecteds and 2 unknowns) was carried
out (Figure 3). The model was specified as autosomal
dominant with 90% penetrance, 1% phenocopy rate, and
disease allele frequency of 0.001. It was run on Genehun-
ter 2.0 software. The disease gene for TAAD in this kin-
dred was mapped to a single interval with a significant
lod score that peaked at the FBN1gene locus (Lod = 3.6,
θ = 0). No other interval had lod score > 1(Figure 4).
Construction of the 15q haplotype with SNPS revealed
recombinations immediately prior to rs668842 and after
rs1072994, refining the linked interval to less than 500
kb. Haplotype analysis indicated the segregation of the
disease haplotype in two family members whose ascend-
ing aorta were assessed as borderline dilated, thus iden-
tifying two individuals with unknown status as mutation
carriers.
Mutation analysis and FBN1 expression
No disease segregating mutation was identified in exons
or exon-intron boundaries of FBN1 genes. No other
intronic mutation was identified which could potentially
affect the splicing. A total of 5 novel and evolutionarily
highly conserved intronic mutations were identified
which did not segregate with the disease. Haplotype
analysis of the affected individuals within this kindred
showed that all the identified intronic mutations reside
on unlinked/non-disease chromosomes and did not
refine the linked interval.
The results from skin biopsies of 3 family members
with TAAD were reported as suggestive for Marfan syn-
drome based on abnormal expression of FBN1 in fibro-
blasts. No images were provided to us by the laboratory.
Discussion
Thoracic aortic aneurysms and dissections in patients
with MFS has very poor outcome. Identification of at
risk individuals prior to an event is therefore of great
importance. In the current study, genome-wide analysis
in a family with non-syndromic TAAD has mapped the
disease gene to MFS disease gene locus. Although muta-
tion carriers in this family did not have syndromic
features of the Marfan syndrome, the aortic disease in
many of the affected family members had a malignant
course. This finding suggests that autosomal dominant
non-syndromic TAAD may be associated with FBN1
gene mutation and implicates the necessity of echocar-
diographic screening of the relatives of patients with
familial TAAD.
Acute aortic aneurysm is an uncommon but potentially
catastrophic illness with an incidence of approximately
2.9/100,000/yr [14]. Predisposing factors are either
acquired such as trauma, caused by complex traits like,
hypertension, and bicuspid aortic valve or inherited such
as in Marfan syndrome. Among these, patients with
Marfan syndrome are especially at high risk for aortic dis-
section of the ascending aorta at a relatively young age
[13]. Patients with familial aneurysms also tend to be
younger and have higher rates of dissection compared to
those with sporadic aneurysms [15], signifying the impor-
tance of early screening of at risk family members.
An analysis of a large database of patients treated at
Yale-New Haven Hospital [16] has shown that patients
with familial autosomal dominant thoracic aortic aneur-
ysms present with complications at much younger
ages (mean 57 years compared to sporadic cases (mean
age 64 years).
Although non-syndromic familial TAAD is a hereditary
disorder, genetic causes of it remain vastly unknown. An
investigation of the families of 158 patients referred for
surgical repair of thoracic aortic aneurysms or dissections
found that first-degree relatives of probands had a higher
risk (risk ratio [RR] 1.8 for fathers and sisters, RR 10.9 for
brothers) of thoracic aortic aneurysms or sudden death
compared with control subjects [1].
At least four different loci have been thus far mapped
for familial non-syndromic thoracic aortic aneurysms.
Mutations in transforming growth factor-beta receptor
type II have been associated with some cases of familial
thoracic aortic aneurysms [5,6]. Mutations in myosin
heavy chain (MYH11), a smooth muscle cell-specific
contractile protein, have been identified in familial
TAAD associated with patent ductus arteriosus (PDA)
Figure 2 Echocardiography image-aneurysm. A left parasternal
view of the ascending aorta in echocardiography examination of an
affected family member with an aneurysm radius of 3.8.
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linked to 16p12.2-12.13[17]. However, some families
have mapped to neither of these loci suggesting addi-
tional loci. We provide a strong evidence for linkage of
non-syndromic familial thoracic aneurysms and dissec-
tions to FBN1 locus. Although a unique phenotype of
aortic dissections involving both the ascending and des-
cending aorta along has been mapped to chromosome
15q in a single kindred [18], we report here for the first
time linkage of a large family with isolated TAAD to
MFS gene locus. All affected individuals and none
among the unaffecteds carry the disease haplotype.
Association between FBN1 mutation and familial non-
syndromic aortic aneurysm has been previously reported
[19]. In the reported kindred, FBN1 mutation segregated
in most but not all family members and there were
mutation carriers who were unaffected. Moreover, some
affected individuals had one or another musculoskeletal
finding of Marfan syndrome. FBN1 mutation has been
also reported in sporadic cases of non-syndromic thor-
acic aneurysm [20]. MFS is a pleiotropic disease and
many of its phenotypes may be absent in one individual
and be present in a close relative. Since the extended
families of patients with TAAD were not examined for
the musculoskeletal phenotypes of Marfan syndrome,
diagnosis of MFS cannot be definitively excluded. More-
over, the proof of causality was based on a single muta-
tion and not genetic linkage analysis.
In this study, we did not identify any disease segregat-
ing mutation in the FBN1 gene in the affected indivi-
duals. Although there may be an unidentified disease
Figure 3 TAAD pedigree. Relationships of members of kindred with TAAD are shown. The index case is indicated by the arrow. Numbered
individuals correspond to those in Additional File 1. Individuals with TAA are indicated by black symbols; individuals without TAA are shown as
unfilled symbols; and individuals who have unknown status are shown as half-gray symbols. Circles represent females; squares represent males.
Symbols with a slash through them indicate deceased subjects. Genotypes of informative SNP markers are shown in their chromosomal order
below the symbol for each individual and their distances from 15pter are indicated in megabases.
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causing mutation within the linked interval unrelated to
FBN1 gene, the small size of the linked interval and the
significant lod score that peaks at FBN1 gene locus
rather indicate that disease in this kindred is caused an
unidentified variation within this gene. It is a general
consensus that absence of FBN1 mutation does not
exclude diagnosis because of high rates of false negative
results, likely due to presence of intronic mutations. In
addition, identification of nonsynonymous mutations in
absence of significant linkage to the disease locus or
clinical criteria is not considered diagnostic for MFS.
There is increasing controversy about significance of
many of the identified FBN1 mutations. FBN1 mutations
can be found in many other conditions that may or may
not overlap with Marfan syndrome such as skin and
skeletal findings (Shprintzen-Goldberg syndrome)[21],
syndrome of mitral valve prolapse, myopia, borderline
aortic enlargement, skin and skeletal findings, Marfanoid
habitus and isolated ectopia lentis. In contrast analysis
of linkage remains one of the most reliable molecular
methods for diagnosis of Marfan syndrome[22]. Most
importantly, the lod-1 interval in this kindred contains
only two other genes (SLC12A1, DYUT) which because
of their tissue distributions and functions cannot be cau-
sative gene for TAAD.
Conclusions
We demonstrate in this study the largest reported kin-
dred with non-syndromic TAAD that unambiguously
links to 15q21, the locus for FBN1 gene. We conclude
that in genetic study of non-syndromic TAAD, FBN1
gene should be considered as one of the candidate
genes. Moreover, the malignant course of the disease in
this kindred underscores the importance of echocardio-
graphic screening in extended relatives of patients with
familial non-syndromic TAAD. Finally, it raises an
important question to whether secondary prevention
strategies employed for Marfan syndrome patients
which include angiotensin converting enzyme inhibitors
should be also examined in patients with early onset
familial TAAD.
Additional material
Additional file 1: Clinical features of the family members according
to the Ghent Nosology. 17 family members of kindred were examined
for musculoskeletal, ocular, pulmonary, cardiovascular, ophthalmologic
and dermatological features of Marfan syndrome based of Ghent
Nosology.
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